Literature DB >> 6116082

Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent.

G R Serjeant, J M Topley, K Mason, B E Serjeant, J R Pattison, S E Jones, R Mohamed.   

Abstract

Since 1952, 112 children with sickle cell anaemia (SCA) in Jamaica have had an aplastic crisis. Outbreaks occurred in 1956, 1960, 1065-67, 1971-73, and 1979-80. Most cases occurred in children under 10 years of age, and an aplastic crisis in a patient over the age of 15 years is rare. There were 38 cases in 1979-80 and stored serum specimens from 28 of these were available for virus studies. Evidence for infection with a parvovirus-like agent was found in 24 of these 28 cases. Viral antigen was detected in 2 patients, both of whom demonstrated seroconversion. Seroconversion during 1980 was detected in a further 7, increasing amounts of antibody during the convalescent period were found in 5, antibody was found in 2 of 4 patients from whom only an acute phase specimen was available and the remaining 10 were antibody positive in the only convalescent phase sample available for testing. Antibody was found in 4 of 94 controls with the SS genotype (in retrospect 2 of these may have had an aplastic crisis) and in 17% of 48 controls with a normal haemoglobin (AA) genotype. The results accord with the possibility that the parvovirus-like agent is the principal cause of aplastic crisis in SCA.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116082     DOI: 10.1016/s0140-6736(81)92739-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  84 in total

1.  Study on clinical characteristics and follow-up visit of acquired aplastic anemia associated with parvovirus B19 infection.

Authors:  Jin-quan Wen; Nan Zhou; Dan Li; Hai-ling Feng; Hua Wang
Journal:  Indian J Pediatr       Date:  2011-08-10       Impact factor: 1.967

2.  CE: Understanding the Complications of Sickle Cell Disease.

Authors:  Paula Tanabe; Regena Spratling; Dana Smith; Peyton Grissom; Mary Hulihan
Journal:  Am J Nurs       Date:  2019-06       Impact factor: 2.220

3.  Hereditary spherocytosis in sisters unmasked by parvovirus infection.

Authors:  N J McLellan; N Rutter
Journal:  Postgrad Med J       Date:  1987-01       Impact factor: 2.401

4.  Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity.

Authors:  Ning Zhi; Ian P Mills; Jun Lu; Susan Wong; Claudia Filippone; Kevin E Brown
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Biological and immunological relations among human parvovirus B19 genotypes 1 to 3.

Authors:  Anna Ekman; Kati Hokynar; Laura Kakkola; Kalle Kantola; Lea Hedman; Heidi Bondén; Matthias Gessner; Claudia Aberham; Päivi Norja; Simo Miettinen; Klaus Hedman; Maria Söderlund-Venermo
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

6.  Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow.

Authors:  H Baurmann; T F Schwarz; J Oertel; S Serke; M Roggendorf; D Huhn
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

7.  Unreviewed reports.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-13

8.  Construction of a recombinant human parvovirus B19: adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus.

Authors:  C H Srivastava; R J Samulski; L Lu; S H Larsen; A Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Pneumonia in young children with homozygous sickle cell disease: risk and clinical features.

Authors:  K De Ceulaer; K W McMullen; G H Maude; R Keatinge; G R Serjeant
Journal:  Eur J Pediatr       Date:  1985-09       Impact factor: 3.183

10.  Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity.

Authors:  Claudia Bönsch; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.